Tag Archive | "termination"

Morphosys regains MOR202 rights from Celgene

Tags: , , , ,

MorphoSys has regained rights to MOR202 from Celgene Read the full story

Eisai returns EZH2 program, including EPZ-6438 to Epizyme

Tags: , , ,

Epizyme has reacquired global rights to its EZH2 program, including EPZ-6438, from its partner Eisai Read the full story

Pfizer terminates spinal muscular atrophy pact with Repligen

Tags: , , ,

Pfizer issued to Repligen a notice of termination for convenience under the License Agreement, dated December 28, 2012 Read the full story

Merck KGaA returns Sym004 to Symphogen

Tags: , , ,

Merck KGaA is conducting an ongoing assessment of its pipeline assets and has decided to return the rights of Sym004 to Symphogen for further development Read the full story

Astellas and Janssen terminate ASP015K deal

Tags: , , , , ,

Astellas Pharma announced that its license agreement with Janssen Biotech, to develop and commercialize ASP015K, oral Janus Kinase (JAK) inhibitor, will end Read the full story

Dynavax regains DV1179 rights after GSK pact termination

Tags: , , ,

Dynavax Technologies has regained full rights to DV1179, an investigational bifunctional inhibitor of toll-like receptors (TLR) 7 and 9 Read the full story

Actavis and Grunenthal terminate Cebranopadol pact

Tags: , , ,

Grunenthal announced the termination of the license agreement with Actavis for the development and commercialization of Cebranopadol Read the full story

Roche terminates interest in Inovio INO-5150 prostate cancer immunotherapy

Tags: , ,

Inovio Pharmaceuticals announced Roche have terminated their 2013 collaboration, option, and license agreement to co-develop INO-5150 Read the full story

Termination of $600 million acquisition of Gamida Cell

Tags: , , ,

Novartis had signed an MOU for acquisition of the stem cell treatment company, Gamida Cell, for up to $600 million. Read the full story

Adcock Ingram rejects CFR Pharmaceuticals $1.2 billion acquisition offer

Tags: , , ,

The board member's Adcock Ingram Holdings, in South Africa, have voted against CFR Pharmaceuticals acquisition proposal.  Read the full story